In a controlled clinical trial the effect of azapropazone (900 mg. daily) was compared with placebo in 18 out-patients with ankylosing spondylitis. The trial was of "crossover" design, and results suggest that azapropazone may be of value in the symptomatic management of ankylosing spondylitis. The side-effects of the drug were mild and occurred with similar frequency during both drug and placebo periods. AZAPROPAZONE, which is related to phenylbutazone, has been developed as an analgesic with anti-inflammatory properties (John and Adrian, 1969). In clinical studies it is well tolerated by patients, and problems of gastrointestinal ulceration and agranulocytosis have not been encountered (Sausgruber, 1971).
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The present study was designed to test whether azapropazone is of value in ankylosing spondylitis and to assess side-effects.
PATIENTS AND METHODS
Twenty-two patients who satisfied the New York criteria (Bennett and Wood, 1969) of definite ankylosing spondylitis were admitted to the trial. All the patients had radiological assessment of the extent of spinal involvement within two years of the trial. The erythrocyte sedimentation rate was elevated above 15 mm. fall/hr. (Westergren) and all patients had complained of backache in the three months preceding the trial. Informed consent was obtained from both patients and their general practitioners before the trial.
Patients were excluded from the trial if they were under 18 years of age, receiving steroids, or if they had peptic ulcers, bowel disease, renal or hepatic disease, or a blood dyscrasia.
Each patient received both azapropazone and placebo for a period of two weeks. The trial was of a double-blind crossover design; neither the patient nor medical staff were aware of which treatment was being given. After an initial "washout" period of one week during which all patients received placebo, they were allocated randomly to receive either azapropazone or placebo for a period of two weeks. At the end of this time they were changed to the alternative therapy. Both azapropazone and placebo were identical in appearance and contained either 300 mg. of azapropazone or lactose. Three capsules were taken each day. Patients were also given a known quantity of pentazocine tablets, 25 mg., to be taken as required for relief of pain. Unused capsules and tablets were returned and counted. No other anti-inflammatory and analgesic treatment was given during the trial.
The patients' symptoms and clinical signs were assessed and several laboratory investigations were made on the first day of the trial (Assessment I), after one week on placebo (Assessment II), then after two weeks on treatment with azapropazone or placebo (Assessment III), and finally after a further two weeks on the alternative treatment (Assessment IV). The assessments were analysed, using the Wilcoxon matched-pairs signed-ranks test, by comparing the grades in both Assessments III and IV with that in Assessment I. Each patient served as his own control and comparisons were not made between different patients. The patient's history and symptoms were recorded by one observer and objective measurements were made by a second independent observer on each occasion at the clinic.
Laboratory investigations included a full blood count, erythrocyte sedimentation rate (ESR-Westergren), serum protein, albumin, bilirubin, alkaline phosphatase, transaminases, sodium, potassium, bicarbonate, chloride, and blood urea, and urine was tested with Bililabstix (Ames Company, Division of Miles Laboratories Ltd., Bucks, England) and sent for microscopy, culture, and sensitivity.
The assessment of symptoms was based on a daily record made by the patient on a diary card and answers to a standard questionnaire which was completed in the clinic.
The diary card was used to record both the severity of back pain (no, some, and severe-graded 0, 1, and 2 respectively) and the number of analgesic tablets consumed daily.
At the clinic the patient's assessment of back pain during the preceding period (none, slight, moderate, and severe-graded 0-3) was recorded. The number of analgesic tablets used was calculated from the number returned and also noted with any possible sideeffects.
The following objective clinical measurements were made: 1. Anterior flexion of the lumbar spine. Three ink marks were made on skin overlying the lumbosacral spine with the subject standing erect. The first at the lumbosacral junction, represented by the spinal intersection of a line drawn through the dimples of Venus. The second was placed 5 cm. below and the third 10 cm. above the lumbosacral junction. The patient was asked to bend as far forwards as possible and the new distance between upper and lower marks was measured. The difference between the distances-i.e. the new distance minus 15 cm.-was recorded (Macrae and Wright, 1969) .
2. Lateral flexion of the lumbar spine. With the patient erect, two marks were made on the skin of the lateral trunk. The upper mark was at a point where a horizontal line through the xiphisternum crossed the coronal line. The lower mark was placed where a horizontal line through the highest point of the iliac crest crossed the coronal line. The distance between these marks was measured in centimetres. The patient leant sideways as far as possible by sliding one hand down the homolateral thigh. The distance between the two marks was again measured. The difference between the two measurements was recorded (Moll, Liyanage, and Wright, 1972) .
3. Thoracic flexion. Two skin marks were made; one corresponded to the mark 10 cm. above the lumbosacral junction previously described and the other was placed over the spine of the seventh cervical vertebra. The difference in the distance between the two marks with the patient erect, and then attempting to arch his back as much as possible, was recorded.
4. Chest expansion-measured at the fourth intercostal space by the method described by Moll and Wright (1973) .
5. Cervical flexion and extension. This was measured by a tape measure in two ways: (a) from the occipital protuberance to the spine of the seventh cervical vertebra; (b) from the chin to the suprasternal notch. The measurements were made with the patient's neck fully extended and then fully flexed.
6. Cervical rotation. A large protractor was fixed to a harness which fitted comfortably over the patient's shoulders. A pointer was strapped to his head so that it was sagittally placed over his nose. The angle through which the pointer moved as the patient rotated his head maximally from one shoulder to the other was measured (Plate I).
RESULTS
Eighteen patients completed the study (Table I) . Their ages were between 28 and 69 years.
Results of mean scores for the patients' subjective assessments are shown in Table II . There was a significant difference in favour of azapropazone on the diary card scores (p<0'05). While taking azapropazone patients used fewer analgesic tablets compared with the placebo period, but in reply to the questionnaire their assessment of pain showed only a small, statistically insignificant preference for the drug.
At the end of the trial two patients spontaneously expressed a preference for azapropazone. None expressed a preference for placebo.
Results from objective clinical measurements are given in Table III . There were changes which, with one exception, were in favour of azapropazone, but none was statistically significant. The results for each measurement of spinal movement were then examined to identify those measurements which were most reproducible and also those which discriminated most between the azapropazone and placebo groups. It was found that, so far as these criteria were concerned, the best measurement in the cervical spine was cervical rotation; for the thoracic spine, chest expansion; and for the lumbar spine, flexion.
The following laboratory investigations showed a difference between the drug and placebo and some were statistically significant. The blood urea level rose with azapropazone (p-0-02), but there was a fall in the ESR (p-0-06), plasma proteins (p-0-01), total red blood count (p-0-03), haemoglobin (p-0-03) and the white blood count (p-0*2). With the exception of the ESR all results remained in the normal range.
Adverse reactions (Table IV) occurred as frequently on azapropazone as on placebo. Nine patients between them had thirteen complaints on azapropazone, and eight patients on placebo had eleven complaints. Gastrointestinal symptoms were more frequent in those treated with azapropazone, but none of those were severe enough to necessitate withdrawal of medication. Frequency of upper respiratory tract infections was also noted, as this has previously been mentioned as a consequence to anti-inflammatory therapy. The reasons for the four patients not completing the study were: side-effects or concurrent illness while on placebo, 2; increasing pain during the initial placebo period 1; lack of cooperation in completing the diary card, 1.
DISCUSSION
This study was designed to see whether azapropazone was of value in ankylosing spondylitis and to assess side-effects.
Dudley Hart (1969) found that no therapeutic agent had produced an objective improvement in the range of spinal movements in ankylosing spondylitis with the exception of a few very early cases. He also noted that patients with ankylosing spondylitis were good discriminators when they were asked to assess new analgesics. The results which we have presented support this view. The only improvement of statistical significance was obtained from the pain score recorded on the diary cards. The objective measurements in this trial may have been poor parameters of assessment, partly because the numbers were so small that large changes in motility needed to occur before statistical significance was reached, and partly because four patients had total bony ankylosis of at least one section of the spine.
Over-all the results of assessments and the fall in ESR suggest that azapropazone has both useful analgesic and anti-inflammatory activity in keeping with the studies of Oyamada (1969) , Gabka and Foltin (1971) , and Mintz and Fraga (1969) . The rise in blood urea level did not become a problem clinically in this study, and the highest rise was 22 mg./lOO ml. producing the highest value of 42 mg./lOO ml. Other studies have shown similar findings without a significant change in creatinine clearance, and it has been postulated that azapropazone may have an effect on protein and aminoacid breakdown (Walker, 1973) .
The fall in the values of the total red blood cell count, haematocrit, and plasma proteins may reflect fluid retention, but we have no direct evidence on this.
The insignificant fall in the white blood cell count was not great and none of the patients' total counts became abnormal. No cases of agranulocytosis attributable to the drug have been reported to the pharmaceutical companies, although it has been in widespread use in seven countries for several years.
The incidence of undesirable symptoms was approximately the same as that found by Godfrey, Calabro, Mills, and Maltz (1972) for phenylbutazone and indomethacin in that about half the patients had some side-effects. This may well be an overestimate, as eight of those on placebo therapy also complained of side-effects. This may have been partly due to the side-effects of the pentazocine tablets consumed for relief of pain. However, since the patient on azapropazone took less tablets it would be reasonable to assume that the incidence of side-effects on placebo would be appreciably lower than on azapropazone. Mezey (1966) puts the incidence of side-effects with azapropazone at 12 %, with the incidence of gastrointestinal side-effects at 7 • 2 %.
The present study suggests that azapropazone may have both useful analgesic and anti-inflammatory properties in ankylosing spondylitis, and over the period of this study is without serious side-effects. We would suggest that azapropazone is deserving of further study involving early cases of ankylosing spondylitis.
GENERAL DISCUSSION (ABRIDGED)
In answer to DR. MATHEWS, who asked what happened to the patients during the week's "wash-out" period, DR. CALCRAFT said that there was a considerable variation in the patients reactions, but he noted that the group who were placed on placebo therapy immediately following the "wash-out" period did very badly. Another curious fact which had come to light was that all the patients seemed to do worse in period III, no matter which of the drugs they started with or which drug they were taking during the third period.
In reply to DR. KERSLEY, who asked about the significance of the rise in blood urea level in relation to long-term treatment, DR. CALCRAFT said that there were insufficient data from his short-term study to answer this question with any assurance, but the manufacturers informed them that most of the trials had shown this initial rise in blood urea level, which did not become significant when the patients were maintained on the drug for longer periods, nor was there any evidence of a fall in the creatinine clearance.
DR. LLOYD interjected that long-term toxicity studies currently taking place in his unit did not indicate any significant rise in the blood urea leyel.
DR. ELL WOOD wanted to be sure, in view of the subjective nature of the assessment of the drug response, whether the patients could distinguish between active and placebo drugs, because of mild side-effects occurring with the former.
DR. CALCRAFT replied that the placebo capsules were indistinguishable from those of the active drug, and that the incidence of recognizable side-effects was extremely low and comparable in both groups, and he was quite confident, in fact, that the patients did not know what they were taking.
In answer to DR. GRAHAME, who asked whether any studies had been made on urate handling in view of the reports that this drug may have uricosuric properties, DR. CALCRAFT said that no such studies had been carried out.
